Company intelligence / Profile preview
InflaRx
Jena, Thuringia, Germanyinflarx.de ↗
- Ownership
- Public · IFRX
- Employees
- ~74
- Development stage
- Other
01
Overview
The company's lead product vilobelimab (GOHIBIC) has received Emergency Use Authorization from the FDA for COVID-19 in hospitalized adults. The company is conducting Phase 3 trials for pyoderma gangrenosum and expects interim analysis in 2025. Phase 2a trials for INF904 in chronic spontaneous urticaria and hidradenitis suppurativa are ongoing with topline data expected in summer 2025.
- Therapeutic areas
- PulmonologyImmunologyDermatologyOncologyInfectious Diseases
- Modalities
- Monoclonal antibodiesSmall molecules
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Beijing Defengrei Biotechnology Co. Ltd.Merck & Co. Inc.
04
Financials
- Market cap
- $199.7M
- Total revenue
- $32.8K
- Enterprise value
- $72.7M
Beyond the preview
Go deeper on InflaRx.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on InflaRx.